NCT00266136View on ClinicalTrials.gov

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,500

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

January 31, 2007

Study Completion Date

October 31, 2012

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

see protocol

DRUG

Thioguanine

see protocol

DRUG

Daunorubicin

see protocol

DRUG

Cyclophosphamide

see protocol

DRUG

G-CSF

see protocol

PROCEDURE

Autologous stem cell transplantation

for details see protocol

PROCEDURE

Allogeneic stem cell transplantation

for details see protocol

Trial Locations (1)

48129

University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology, Münster

All Listed Sponsors
collaborator

Deutsche Krebshilfe e.V., Bonn (Germany)

OTHER

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

University Hospital Muenster

OTHER

NCT00266136 - Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | Biotech Hunter | Biotech Hunter